Small Fiber Neuropathy in Pernicious Anemia

A pattern of nerve damage standard testing is not built to detect

Pernicious Anemia Can Cause Small Fiber Neuropathy, a Distinct Pattern of Nerve Injury

Pernicious anemia is described most often as a cause of subacute combined degeneration, injury to the spinal cord’s dorsal columns and corticospinal tracts. This is the pattern of nerve damage most documented in PA literature and most familiar to physicians who recognize the disease at all.

It is not the only pattern.

B12 deficiency also damages small sensory nerve fibers, producing a distinct condition called small fiber neuropathy. This injury follows a different mechanism than spinal cord degeneration, produces different symptoms, and is missed by the nerve testing most patients receive when they report burning, tingling, or pain in their hands and feet.

A patient can have normal or only mildly abnormal results on standard nerve conduction testing and still have significant small fiber damage. The test was never built to detect it.

This guide explains what small fiber neuropathy is, how B12 deficiency causes it, why standard testing misses it, and what determines whether treatment is working.

Small Fiber Neuropathy Involves a Distinct Set of Nerves

Peripheral nerves are not one uniform structure. They divide into distinct fiber types, classified by size and by how much myelin, the fatty insulating sheath around a nerve fiber, they carry.

Large fibers are thickly myelinated. They carry signals for vibration sense, position sense, and reflexes. Damage to large fibers produces the classic findings of subacute combined degeneration: loss of balance, unsteady gait, reduced or absent reflexes, and impaired vibration sense. These are the findings a standard neurological exam and nerve conduction study are designed to detect.

Small fibers are different. A-delta fibers carry a thin myelin sheath. C fibers carry none at all.¹ Both types are smaller in diameter than large fibers, and both transmit different information: pain, temperature, itch, and a range of autonomic signals that regulate sweating, blood vessel constriction, and other involuntary functions.

Damage to small fibers does not produce the balance problems or reflex changes associated with large fiber injury. It produces burning, stabbing pain, altered temperature sensation, and other sensory disturbances, often in a glove-and-stocking distribution starting in the feet and hands and moving proximally as it progresses.²

Because small and large fibers are structurally different and carry different information, damage to one does not require or predict damage to the other. A patient can have significant small fiber injury while large fiber function, and the tests that measure it, remain normal.

B12 Deficiency Injures Small Fibers Through Two Distinct Mechanisms

Small fiber neuropathy in B12 deficiency does not arise from a single injury pathway. The two fiber types that make up the small fiber category, A-delta and C fibers, are harmed differently.

A-delta fibers carry a thin myelin sheath, and B12 is required to maintain it. B12 supports the methylation reactions that regulate myelin protein synthesis and structural maintenance throughout the nervous system, centrally and peripherally.³ When B12 is deficient, this maintenance fails. The mechanism is the same one responsible for the demyelination seen in subacute combined degeneration, applied here to thin peripheral myelin rather than the thick tracts of the spinal cord.

C fibers carry no myelin, so this mechanism does not apply to them. Their injury comes from a different source: the buildup of methylmalonic acid, a metabolite that accumulates when B12-dependent enzymes can no longer convert it to a usable form.⁴ Elevated methylmalonic acid disrupts mitochondrial energy production and generates oxidative stress inside the axon itself. Laboratory studies exposing nerve and Schwann cells directly to methylmalonic acid have shown measurable damage to cell viability and mitochondrial function.⁵ This is axonal injury, not demyelination, and it explains why C fibers are vulnerable even though they have no myelin to lose.

This two-pathway explanation, myelin maintenance failure for A-delta fibers and metabolite-driven axonal injury for C fibers, reflects the clearest mechanisms currently supported by the evidence. Other contributing factors, including oxidative stress and inflammatory signaling, are also under investigation and may play a role.

This distinction matters for what happens after treatment starts. Methylmalonic acid levels typically fall within about a week of starting B12 injections. That drop reflects a change in blood chemistry, not a change in nerve tissue. Stopping the buildup of a toxic metabolite likely halts further axonal injury, but it does not repair the axon that has already been damaged. Nerve regeneration operates on a separate and much slower timeline than a laboratory marker clearing from serum, and it can take anywhere from weeks to years. Some injury may not resolve at all.

A patient whose methylmalonic acid has normalized has confirmation that the metabolic insult has been addressed. It is not confirmation that the nerve has recovered.

Symptoms Reflect the Fibers Involved, and So Does the Differential

Small fiber neuropathy produces a distinct symptom pattern, different from the balance and coordination problems associated with large fiber damage. The most commonly reported symptoms are burning, pain, tingling, numbness, and itch, typically starting in the feet and hands in a glove-and-stocking distribution.

Itch deserves specific mention because it is easy to dismiss as a skin problem rather than a neurological one. In large cohort studies of small fiber neuropathy patients, itch was reported by roughly two-thirds of patients, at a rate comparable to burning and pain.^6,7 It follows a recognizable pattern: worse in the evening and at night, and concentrated in the distal limbs before spreading. A patient describing nighttime itching in the hands and feet, with no rash or visible skin cause, is describing a documented small fiber symptom, not an unusual one.

B12 deficiency is one identifiable cause of small fiber neuropathy, but not the only one. Diabetes and impaired glucose tolerance, autoimmune conditions, and inherited sodium channel mutations are among the most commonly identified causes. Despite thorough workup, no cause is found in roughly half of all cases.⁸

Several of the most common non-PA causes carry their own substantial connection to B12 deficiency, through mechanisms unrelated to pernicious anemia.

Metformin, the first-line medication for type 2 diabetes, impairs B12 absorption, and long-term users show significantly elevated rates of B12 deficiency.^9,10,11 Whether this specific deficiency drives the neuropathy in diabetic patients remains unsettled in the research, but the deficiency itself is common enough, and clinically similar enough to diabetic neuropathy, that it is frequently overlooked and left untreated. This pattern has been documented primarily in older adults, but the underlying mechanism is not age-specific, and there is no reason to expect it behaves differently in younger metformin users, who may be even less likely to have B12 deficiency considered as an explanation for their symptoms.

Hypothyroidism carries B12 deficiency rates as high as 10 to 40 percent, driven by shared autoimmune susceptibility with pernicious anemia as well as separate absorption problems, including slowed gut motility and bacterial overgrowth.¹²

Celiac disease can impair B12 absorption through several distinct mechanisms: reduced stomach acid from atrophic gastritis, impaired pancreatic function, and increased risk of small intestinal bacterial overgrowth.¹³

Sjögren’s syndrome shows the strongest association of any of these conditions. One case-control study found B12 deficiency in nearly 43 percent of Sjögren’s patients, compared to about 11 percent of controls, even after excluding pernicious anemia and adjusting for other known causes. The proposed mechanism is food-cobalamin malabsorption, distinct from the intrinsic factor failure that defines PA.¹⁴

The remaining share of cases, roughly a third to half, are never traced to any identified cause at all, including B12 deficiency. This does not mean B12 has been ruled out. As established earlier, serum B12 does not reliably detect functional deficiency, regardless of which condition or mechanism is impairing delivery to cells. Ruling out a B12 contribution in any of these differential-cause patients, PA or otherwise, requires the same functional evaluation described throughout this guide: methylmalonic acid, holotranscobalamin, and clinical response to treatment, not a normal serum level alone.

Testing Cannot Reliably Confirm or Rule Out Small Fiber Involvement

Standard nerve conduction studies measure how quickly and strongly a signal travels through large, myelinated fibers. This is the test most patients receive when they report tingling, numbness, or burning in their hands and feet, and it is the test most physicians rely on to determine whether nerve damage is present.

It cannot detect small fiber damage. A-delta and C fibers are too thin and, in the case of C fibers, unmyelinated, to generate a signal nerve conduction testing can measure. A patient can have substantial small fiber injury and a completely normal nerve conduction study. A “mild” or “normal” result from years ago does not rule out small fiber involvement, then or now, because the test was never assessing that fiber population in the first place.

Tools that can detect small fiber damage exist, but each comes with real limitations.

Skin punch biopsy, measuring intraepidermal nerve fiber density, is considered the diagnostic gold standard.^15,16 It is a minor, in-office procedure. But it depends on a physician who already suspects small fiber neuropathy specifically, since it is not part of standard neurological workup and most physicians do not order it reflexively. Samples require processing at a specialized lab equipped to compare results against age- and sex-matched normative data, which limits where the test can be done. Even when performed and interpreted correctly, biopsy sensitivity is imperfect, positive in roughly two-thirds of patients suspected of having small fiber neuropathy on clinical grounds. A normal result does not exclude the diagnosis.¹⁷

Newer electrophysiological techniques, including sympathetic skin response and cutaneous silent period testing, can detect small fiber dysfunction, including subclinical cases with normal nerve conduction studies.¹⁸ These tools remain largely confined to research and specialized clinical settings and are not part of routine diagnostic practice.

The practical result is that a patient cannot rely on testing to confirm or exclude small fiber neuropathy. The tools that exist are either blind to it, as with nerve conduction studies, or inaccessible and imperfect, as with biopsy and specialized electrophysiology. This is the same conclusion reached elsewhere in B12-related illness: the absence of confirmatory testing is not evidence against the diagnosis.

Treatment Adequacy Is Measured by Symptom Resolution, Not Labs or Tests

Given that testing cannot reliably confirm or rule out small fiber neuropathy, treatment adequacy has to be judged by something else: whether symptoms improve.

The standard approach to B12 deficiency applies here as it does elsewhere. Injections bypass the failed absorption pathway and correct the underlying deficiency. Methylmalonic acid typically normalizes within about a week.¹⁹ That normalization confirms the metabolic driver of C fiber injury has been addressed. It does not confirm the nerve has healed, and it should not be used as a stopping point for evaluating treatment.

The relevant measure is the symptom itself, tracked over time. Improvement, plateau, or worsening in burning, pain, tingling, or itch is the signal that matters, not a lab value. If symptoms are not improving or are worsening despite adequate dosing and frequency, that is clinical evidence the current treatment approach is insufficient, whether the cause is inadequate injection frequency, a coexisting condition contributing independently to the neuropathy, or the limits of what nerve tissue can still recover.

Recovery itself has a range of possible outcomes. Some patients see substantial improvement. Some see partial improvement with residual symptoms. Some see little change at all. This range is documented in the available case literature: reports exist of substantial improvement in small fiber measures after B12 replacement, and reports exist of neuropathy that was arrested but left permanent residual findings on follow-up years later.^1,3 The degree of recovery is influenced by how long the deficiency went uncorrected before treatment began and how much axonal injury had already occurred, not by effort or consistency with treatment.

Full resolution is not guaranteed. It is also not something a patient should assume is impossible. The only way to know is to treat, and to track the symptom.

Small Fiber Neuropathy Reveals a Broader Diagnostic Blind Spot

Small fiber neuropathy is not a rare curiosity in pernicious anemia. It is a predictable consequence of how B12 deficiency injures nerve tissue, and it sits in a specific gap in how that injury gets found.

Standard nerve conduction testing was built to detect large fiber damage, and it does that well. It says nothing about small fibers, and a normal or mildly abnormal result is not evidence they are unaffected. The tools built specifically to detect small fiber damage exist, but they are inaccessible to most patients, dependent on a physician already suspecting the diagnosis, and imperfect even when used correctly.

This leaves symptoms as the most reliable evidence available. Burning, pain, tingling, and itch in a glove-and-stocking pattern, particularly at night, are not vague complaints to be dismissed because a nerve conduction study came back clean. They are the clinical picture, and in the absence of a test that can reliably confirm or exclude small fiber involvement, the clinical picture is what treatment decisions have to be built on.

A patient with these symptoms, a history of B12 deficiency or a condition known to impair B12 delivery, and normal standard nerve testing has not been ruled out. They have been tested with the wrong tool.

References

1. Güneş HN, Bekircan-Kurt CE, Tan E, Erdem-Özdamar S. The Histopathological Evaluation of Small Fiber Neuropathy in Patients with Vitamin B12 Deficiency. Acta Neurologica Belgica. 2018;118(3):405-410. View source
2. Pál E. Small Fiber Neuropathy: Clinicopathological Correlations. Behavioural Neurology. 2020;2020:8796519. https://doi.org/10.1155/2020/8796519
3. Agircan D, Bal N, Gesoglu-Demir T, Gocmen A, Ethemoglu O. The Electrophysiological Evaluation of Small Fiber Neuropathy in Symptomatic Patients with Vitamin B12 Deficiency before and after Treatment. Neurological Sciences and Neurophysiology. 2024;41(3):182-189. https://doi.org/10.4103/nsn.nsn_92_24
4. Methylmalonic acid – key marker of vitamin B12 status and metabolism. biocrates life sciences. 2025. View source
5. Methylmalonic Acid Accumulation and the Development of Peripheral Neuropathy. Neurology. 2012;78(1 Suppl):P03.190 [abstract]. View source
6. Kool D, Hoeijmakers JGJ, Faber CG, Merkies ISJ. Where Does It All Itch? Exploring the Characteristics of Pruritus in Small Fiber Neuropathy. Journal of the Peripheral Nervous System. 2025;30(3):e70041. https://doi.org/10.1111/jns.70041
7. Brenaut E, Marcorelles P, Genestet S, Ménard D, Misery L. Pruritus: An Underrecognized Symptom of Small-Fiber Neuropathies. Journal of the American Academy of Dermatology. 2015;72(2):328-332. https://doi.org/10.1016/j.jaad.2014.10.034
8. Murin PJ. Small Fiber Neuropathy. MedLink Neurology. Updated 2025. View source
9. Ahmed MA, Muntingh G, Rheeder P. Vitamin B12 Deficiency in Metformin-Treated Type-2 Diabetes Patients: Prevalence and Association with Peripheral Neuropathy. BMC Pharmacology and Toxicology. 2016;17(1):44. https://doi.org/10.1186/s40360-016-0088-3
10. Sepassi A, et al. Associations between Long-Term Metformin Use, the Risk of Vitamin B12 Deficiency, and Neuropathy: An All of Us Research Program Study. Diabetes Research and Clinical Practice. 2025;228:112424. https://doi.org/10.1016/j.diabres.2025.112424
11. Alvarez M, Prieto AE, Portilla N, Moya D, Rincon O, Guzman I. Metformin-Induced Vitamin B12 Deficiency: An Underdiagnosed Cause of Diabetic Neuropathy. World Journal of Diabetes. 2025;16(7):107514. https://doi.org/10.4239/wjd.v16.i7.107514
12. Aon M, Taha S, Mahfouz K, Ibrahim MM, Aoun AH. Vitamin B12 (Cobalamin) Deficiency in Overt and Subclinical Primary Hypothyroidism. Journal of Investigative Medicine High Impact Case Reports. 2022. https://doi.org/10.1177/11795514221086634
13. Glossary: Vitamin B12 and Celiac Disease. Celiac Disease Center at Columbia University Medical Center. View source
14. Association of Primary Sjögren’s Syndrome and Vitamin B12 Deficiency: A Cross-Sectional Case-Control Study. Journal of Clinical Medicine. 2020;9(12):4063. View source
15. Samolis A, Troupis T, Politis C, Pantazis N, Triantafyllou G, Tsakotos G, Tegos T, Lazaridis N, Natsis K, Piagkou M. Intraepidermal Nerve Fiber Density as an Indicator of Neuropathy Predisposition: A Systematic Review with Meta-Analysis. Diagnostics. 2025;15(11):1311. https://doi.org/10.3390/diagnostics15111311
16. Nolano M, Tozza S, Caporaso G, Provitera V. Contribution of Skin Biopsy in Peripheral Neuropathies. Brain Sciences. 2020;10(12):989. https://doi.org/10.3390/brainsci10120989
17. Diagnosing Small Fiber Neuropathy Through the Use of Skin Biopsy. Practical Neurology. October 2009. View source
18. Issi ES. Assessment of Possible Small Fiber Neuropathy in Early-Stage Vitamin B12 Deficiency Using Electrophysiological Methods. Arquivos de Neuro-Psiquiatria. 2025;83:s00451811722. https://doi.org/10.1055/s-0045-1811722
19. Wentworth BJ, Copland AP. Revisiting Vitamin B12 Deficiency: A Clinician’s Guide for the 21st Century. Practical Gastroenterology. 2018;42(12):28-47. View source